Ok, but what of the 6 of 51, or 12% that discontinued narcotic use?
Is that subjective?
I guess you are similar to most people looking at clinical data, pick whatever they want to see. Does 6 of 51 discontinue narcotic use means the drug works? What about the 8 patients who increased narcostic use? Does that mean the drug doesn't work? That's not how I look at clinical data. I look at data as whole, all I want to know whether the data are reasonablely predictive of phase III (306/307) success. From these data, I can't tell. Due to the dramatic bone scan result, I expected more. Maybe this expectation is unrealistic, because we don't know what bone scan data really mean, and the degree they correspond to direct clinical benefit. This uncertainty can be mitigated by direct correlation between bone scan data and pain relief data, which in return would establish it as predictor of clinical benefit. That's what I want to see.
Market Data 
Markets 
AI
